Keros Therapeutics (KROS) Misses Q1 EPS by 18c
Tweet
Share
E-mailGet Alerts KROS Hot Sheet
Join SI Premium – FREE
Keros Therapeutics (NASDAQ: KROS) reported Q1 EPS of ($1.21), $0.18 worse than the analyst estimate of ($1.03). Revenue for the quarter came in at $370 thousand versus the consensus estimate of $1.69 million.
For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Star Equity Holdings (STRR) Misses Q2 EPS by 8c
- Full Circle Lithium closes $5.14M private placement
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
